Image Place holder

Chetasi Talati, MD


Specialty: Hematology/Oncology
Program: Malignant Hematology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Cancer Types Treated: Leukemia , MDS, Myelodysplastic Syndromes (MDS)

Dr. Talati is an Assistant Member at Moffitt Cancer Center in the Department of Malignant Hematology.  She earned her MD from American University of Antigua College of Medicine (Kasturba Medical College, India), completed an Internal Medicine Residency at University at Buffalo (SUNY Buffalo), and completed a Hematology and Medical Oncology Fellowship at the University of South Florida College of Medicine and Moffitt Cancer Center. Dr. Talati’s clinical interests include management of patients with myeloid malignancies with a focus on Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndromes (MDS).  Dr. Talati’s research interests include optimizing the current prognostic systems and treatment strategies for patients with myeloid malignancies, with particular interest in designing early phase clinical trials for patients with AML.

Education & Training

Board Certification:

  • Internal Medicine

Fellowship:

  • USF/Moffitt Cancer Center - Hematology Oncology

Residency:

  • University of Buffalo - Internal Medicine

Medical School:

  • American University of Antigua College of Medicine - MD
Participating Trials

CLINICAL TRIAL 19742
Phase 1/1b Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia
Condition: Malignant Hematology
Intervention: Minnelide
Open

CLINICAL TRIAL 19379
A Phase 2, Multicenter, Open-Label Study To Evaluate The Efficacy And Safety Of Luspatercept (Ace-536) In Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis And Anemia With And Without Red Blood Cell-Transfusion Dependence
Condition: Malignant Hematology
Intervention: ACE-536 (Luspatercept); Luspatercept
Open

CLINICAL TRIAL 19737
S1712, " A Randomized Phase II Study of Ruxolitinib in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease.- Study Chairs: Kendra Sweet, M.D., Jerald P. Radich, M.D.
Condition: Malignant Hematology
Intervention: AMN107 (Nilotinib); Dasatinib (BMS-354825); Jakafi (Ruxolitinib); Nilotinib; Ruxolitinib; Tasigna (Nilotinib)
Open

CLINICAL TRIAL 19825
A Phase III Multicenter, Randomized, Open Label Study of APR-246 in Combination with Azacitidine Versus Azacitidine Alone for the Treatment of TP53 Mutant Myelodysplastic Syndromes
Condition: Malignant Hematology
Intervention: APR-246; azacitidine (5-azacitidine)
Open

CLINICAL TRIAL 19870
A Phase 1, Multi-center, Open-label Study of IMGN632 Administered Intravenously in Patients with Relapsed/Refractory CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
Condition: Malignant Hematology
Intervention: IMGN632
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Talati C, Dhulipala VC, Extermann M, Al Ali N, Kim J, Komrokji R, Sweet K, Kuykendall A, Sehovic M, Reljic T, Djulbegovic B, Lancet JE. Comparisons of commonly used frontline regimens on survival outcomes in patients age 70 years and older with acute myeloid leukemia. Haematologica. 2019 May. Pubmedid: 31073071.
  • Chan O, Talati C, Sweet K, Pinilla-Ibarz J. Can increased immunogenicity in chronic myeloid leukemia improve outcomes?. Expert Rev Hematol. 2019 Mar;12(4):225-233. Pubmedid: 30855193.
  • Pavlovsky C, Chan O, Talati C, Pinilla-Ibarz J. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia. Future Oncol. 2019 Jan;15(3):257-269. Pubmedid: 30251548.
  • Andrew K, Talati C, Padron E, Sweet K, Sallman D, List AF, Lancet JE, Komrokji RS. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients. Am J Hematol. 2019 Jan;94(1):87-92. Pubmedid: 30390311.
  • Talati C, Sallman D, List AF. SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q. Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):629-635. Pubmedid: 30097406.
  • Talati C, Sweet K. Recently approved therapies in acute myeloid leukemia: A complex treatment landscape. Leuk Res. 2018 Oct;73:58-66. Pubmedid: 30223250.
  • Talati C, Sweet KL. Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectives. Int J Hematol Oncol. 2018 Oct;7(3):IJH04. Pubmedid: 30405902. Pmcid: PMC6219429.
  • Talati C, Lancet JE. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia. Future Oncol. 2018 May;14(12):1147-1154. Pubmedid: 29378418.
  • Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol. 2018 Mar;97(3):435-441. Pubmedid: 29189896.
  • Talati C, Pinilla-Ibarz J. Resistance in chronic myeloid leukemia: definitions and novel therapeutic agents. Curr Opin Hematol. 2018 Mar;25(2):154-161. Pubmedid: 29266016.
  • Sandoval-Sus JD, Chavez JC, Dalia S, Naqvi SMH, Talati C, Nodzon L, Kharfan-Dabaja MA, Pinilla-Ibarz J. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia. Leuk Lymphoma. 2018 Jan;59(1):59-68. Pubmedid: 28641468.
  • Talati C, Sallman D, List A. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond. Semin Hematol. 2017 Jul;54(3):159-166. Pubmedid: 28958290.
  • Kuykendall AT, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS. The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval. Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e45-e53. Pubmedid: 28869184.
  • Kim DW, Talati C, Kim R. Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy. J Gastrointest Oncol. 2017 Apr;8(2):256-265. Pubmedid: 28480065. Pmcid: PMC5401857.
  • Talati C, Zhang L, Shaheen G, Kuykendall A, Ball M, Zhang Q, Lancet JE, Zuckerman KS, List AF, Komrokji R, Moscinski L, Padron E. Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis. Blood. 2017 03;129(13):1881-1883. Pubmedid: 28159734.
  • Talati C, Griffiths EA, Wetzler M, Wang ES. Polo-like kinase inhibitors in hematologic malignancies. Crit Rev Oncol Hematol. 2016 Feb;98:200-210. Pubmedid: 26597019.
  • Talati C, Padron E. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T. Curr Hematol Malig Rep. 2016 Dec;11(6):425-433. Pubmedid: 27664113.
  • Wei L, Liu S, Conroy J, Wang J, Papanicolau-Sengos A, Glenn ST, Murakami M, Liu L, Hu Q, Conroy J, Miles KM, Nowak DE, Liu B, Qin M, Bshara W, Omilian AR, Head K, Bianchi M, Burgher B, Darlak C, Kane J, Merzianu M, Cheney R, Fabiano A, Salerno K, Talati C, Khushalani NI, Trump DL, Johnson CS, Morrison CD. Whole-genome sequencing of a malignant granular cell tumor with metabolic response to pazopanib. Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000380. Pubmedid: 27148567. Pmcid: PMC4850888.
  • Talati C, Ontiveros EP, Griffiths EA, Wang ES, Wetzler M. How we will treat chronic myeloid leukemia in 2016. Blood Rev. 2015 Mar;29(2):137-142. Pubmedid: 25555325. Pmcid: PMC4385463.
  • Thirunavukarasu P, Talati C, Munjal S, Attwood K, Edge SB, Francescutti V. Effect of Incorporation of Pretreatment Serum Carcinoembryonic Antigen Levels Into AJCC Staging for Colon Cancer on 5-Year Survival. JAMA Surg. 2015 Aug;150(8):747-755. Pubmedid: 26083632.